GLP-1 vs Metformin Weight Loss

Summary: Metformin causes about 5 to 10 pounds of long-term weight loss; GLP-1s like semaglutide and tirzepatide produce 15 to 22 percent body weight loss, and the two are commonly combined in type 2 diabetes care.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

The short answer: GLP-1 receptor agonists win on raw weight loss, and it is not close. Semaglutide produces about 15% mean body weight loss in non-diabetic adults with obesity ^[2], tirzepatide produces about 20.9% at the 15 mg dose ^[3], and metformin produces roughly 4 to 7 pounds of long-term loss ^[1]. That gap is the headline. The rest of the article is about why metformin still belongs in the conversation, why most people with type 2 diabetes end up on both, and how to think about cost when one drug is $4 a month and the other is over $1,000.

The numbers, side by side

A few things stand out. Metformin's effect is real but modest. The DPP showed about a 2 kg sustained difference versus placebo across a decade of follow-up ^[1], and in everyday endocrinology practice the typical loss tracks closer to 5 to 10 pounds. GLP-1 monotherapy is a different category entirely. At full dose, semaglutide gets a 200 pound adult down to roughly 170. Tirzepatide gets them to about 158. Metformin gets them to about 195.

That is not a small difference. It is a difference in what the drug is for.

How each one actually works

Metformin and GLP-1 medications target completely different parts of metabolism. Knowing which lever each one pulls is the cleanest way to understand why the weight loss numbers diverge.

Metformin: AMPK and hepatic glucose

Metformin is a biguanide. Its primary action is on the liver. It reduces hepatic gluconeogenesis, which means your liver dumps less sugar into the bloodstream between meals. It also activates AMP-activated protein kinase (AMPK), an energy sensor that nudges cells toward burning fuel rather than storing it. A secondary effect is improved peripheral insulin sensitivity, so the insulin your pancreas does release works harder.

Metformin does not act on appetite signaling. It does not slow gastric emptying. It does not change how full you feel after a meal. Any weight loss it produces is indirect: better insulin sensitivity reduces fat storage pressure, and the GI side effects (nausea, loose stools) cause some people to eat slightly less while their gut adapts. That is why the weight loss is modest and why it plateaus.

GLP-1 agonists: incretin pathway and appetite

Semaglutide, liraglutide, and dulaglutide are GLP-1 receptor agonists. Tirzepatide adds GIP receptor agonism on top of GLP-1, which is why its weight loss results edge ahead. The mechanism is multi-pronged. The drug binds GLP-1 receptors in the pancreas, gut, and brain. In the pancreas it stimulates glucose-dependent insulin release and suppresses glucagon. In the gut it slows gastric emptying. In the hypothalamus it acts on appetite circuits, reducing hunger and food preoccupation.

That last effect is what patients describe as "food got quieter." The biological pressure to overeat drops. People do not feel like they are dieting harder. They feel like the constant background noise around food has been turned down. That is why GLP-1s produce weight loss in a range metformin cannot reach. They address a different bottleneck.

Cost is the other half of the conversation

The pharmacology gap and the cost gap run in opposite directions. The cheaper drug delivers less weight loss. The more effective drug costs hundreds of times more.

If you have type 2 diabetes, your insurance will almost always cover metformin and will usually cover a GLP-1 with prior authorization. If you do not have diabetes and you want a GLP-1 for weight, you are likely paying out of pocket unless your employer plan specifically covers anti-obesity medications. Most do not.

That economic reality drives a lot of prescribing patterns. Metformin is often the first treatment offered, not because it is the strongest tool but because it works well enough for early-stage problems and almost everyone can afford it.

When metformin is the right first move

There are clear scenarios where metformin is the correct starting drug even when GLP-1s would produce more weight loss.

You are cost-sensitive. A GLP-1 at full price is not sustainable for most people without insurance. Metformin at $4 a month is.

Your goal is modest weight loss, not transformation. Losing 5 to 10 pounds to nudge your A1c down from 6.5% to 6.0% is a job metformin can do.

You are newly diagnosed with type 2 diabetes and your A1c is under 8%. The American Diabetes Association still names metformin as a foundational option for many patients, and decades of safety data back that up ^[4].

You have prediabetes. The DPP showed metformin cut progression to type 2 diabetes by 31% over three years, with the benefit sustained at 10 and 15 years of follow-up ^[1]. That is a remarkable risk reduction for a generic pill.

You have polycystic ovary syndrome (PCOS) without significant obesity. Metformin improves insulin sensitivity and menstrual regularity in PCOS, often without the cost and titration burden of a GLP-1.

You cannot tolerate injections, or oral semaglutide (Rybelsus) is not an option in your formulary.

When a GLP-1 is the right call from day one

The other side of the decision is just as clear. If your situation matches any of these, starting with a GLP-1 (and possibly adding metformin alongside) is the more rational path.

Your BMI is 30 or above and weight is the main driver of metabolic risk. The 15 to 22% body weight loss from semaglutide or tirzepatide will do more for your cardiometabolic profile than the 2 to 5% metformin can offer.

You have type 2 diabetes with established cardiovascular disease. Semaglutide and other GLP-1s reduce major adverse cardiovascular events in this population. Metformin's cardiovascular benefit is real but weaker.

You have tried dieting repeatedly and the limiting factor is hunger, not motivation. This is the biology metformin does not touch. GLP-1s do.

Your A1c is above 8.5% and you need both glucose control and weight loss in the same intervention.

You have obesity without diabetes and you have access (insurance, employer benefits, or budget) for Wegovy, Zepbound, or compounded options.

Using them together is extremely common

The framing of "metformin vs GLP-1" sets up a false choice for people with type 2 diabetes. In real endocrinology practice, combination therapy is the default once a GLP-1 enters the picture. The American Diabetes Association's 2026 Standards of Care explicitly supports combining metformin with GLP-1 agonists, and most patients on a GLP-1 for T2D are already taking metformin ^[4].

The two drugs do not duplicate each other. Metformin handles hepatic glucose output and insulin sensitivity. The GLP-1 handles incretin signaling, gastric emptying, and appetite. Combining them covers more of the disease process than either does alone, and the side-effect profiles do not stack badly. The GI symptoms from each drug are similar (nausea, loose stools, indigestion), so titrating slowly when starting the second one is the standard approach.

How long does metformin take to work?

Glucose effects appear within a few days of starting metformin and stabilize over 2 to 3 months. Weight loss is slower. Most people who lose weight on metformin see the change over 6 to 12 months, and the curve is gentle. There is no "metformin moment" where the appetite shifts the way it does on a GLP-1.

If you are 3 months in on a target dose (usually 1,500 to 2,000 mg daily) and you have not lost any weight, you are unlikely to see dramatic change by staying on it. That is when many clinicians add a GLP-1 if weight is the driving concern.

For comparison, semaglutide and tirzepatide produce noticeable appetite changes within the first 2 to 4 weeks at the starting dose, and meaningful weight loss accumulates over the full titration period (16 to 20 weeks to reach maintenance dose). The full effect lands at month 6 to month 12.

Does metformin cause weight loss?

Yes, modestly. The honest answer most endocrinologists give is "it might, and if it does it will be 5 to 10 pounds." Calling metformin "a weight loss pill" overstates what it does. It is a glucose-lowering drug whose effects on body weight are real but secondary to its main job. The FDA has not approved metformin for weight loss in any patient population, including people without diabetes.

Studies in non-diabetic adults with obesity show metformin produces about 2 to 3% body weight loss over 6 to 12 months. That is meaningfully less than the 15 to 22% range of GLP-1s, and it is in the same ballpark as placebo plus lifestyle changes in the major weight loss trials.

If your goal is a clinically significant body weight reduction (5% or more, which is the threshold the FDA uses for obesity medication approval), metformin alone is not the right tool.

What about topiramate? And other adjacent options

Topiramate (Topamax) often comes up in the same conversation because it is another oral medication associated with weight loss. It is an anti-seizure drug used off-label and as a component of Qsymia (phentermine plus topiramate ER) for obesity. Average weight loss with Qsymia at the top dose is around 9.8% body weight at 1 year, which sits between metformin and the GLP-1s.

Topiramate alone takes 4 to 8 weeks to start affecting appetite, and the full effect on weight typically lands at 3 to 6 months. The side-effect profile is different from metformin and GLP-1s. Cognitive slowing, tingling in the hands and feet, and changes in taste (especially with carbonated drinks) are common. It is not a first-line choice for most people but can be the right answer for someone who has tried other options.

Topiramate is not a GLP-1 and not in the same drug class as metformin. If you are deciding between metformin and a GLP-1, topiramate is a separate conversation for later.

Metformin in special situations

Metformin for Hashimoto's and thyroid-related weight gain

Metformin does not directly treat hypothyroidism and is not a weight loss treatment for Hashimoto's. Some research suggests metformin may slightly improve TSH levels in people with hypothyroidism on levothyroxine, but the weight effect in this population is similar to the general modest 5 to 10 pound range. If your weight gain is being driven primarily by undertreated hypothyroidism, the answer is correct thyroid replacement, not adding metformin.

If your weight gain has multiple drivers (hypothyroidism plus insulin resistance plus age-related metabolic slowing), metformin can be one piece of the plan. A GLP-1 will still produce larger weight changes.

Metformin for PCOS

This is one of metformin's strongest non-diabetes indications. PCOS frequently involves insulin resistance, and metformin can improve menstrual regularity, reduce androgen levels, and produce modest weight loss in this population. For PCOS patients who are not significantly overweight, metformin alone is often enough. For PCOS patients with obesity, GLP-1s are increasingly used either alongside metformin or instead of it.

The decision in one paragraph

If cost is a hard constraint, start with metformin. If your goal is moderate weight loss (5 to 10 pounds) and glucose control, metformin alone may be enough. If you need substantial weight loss (more than 10% of body weight), a GLP-1 is the more effective tool by a wide margin and metformin alone will not get you there. If you have type 2 diabetes, the answer is usually both, started in whichever order matches your most pressing problem. If you have obesity without diabetes and you can access a GLP-1, that is the rational starting point. Metformin can be added later if needed.

Common questions about GLP-1 vs metformin for weight loss

Can you take metformin and a GLP-1 together for weight loss?

Yes. Combining metformin with a GLP-1 is standard practice in type 2 diabetes care, and the drugs work through different mechanisms so they complement each other rather than overlap.

How much weight will I lose on metformin?

Most people lose 5 to 10 pounds on metformin over 6 to 12 months. Some lose more, some lose none. The Diabetes Prevention Program found about 2 kg of sustained loss at 10 years compared to placebo.

How much weight will I lose on a GLP-1?

Semaglutide produces about 15% body weight loss at full dose over 68 weeks. Tirzepatide produces 15 to 21% depending on dose. A 200 pound adult would lose 30 to 42 pounds on average.

Does metformin cause weight loss in people without diabetes?

Modestly. Studies in non-diabetic adults with obesity show about 2 to 3% body weight loss over 6 to 12 months. It is not FDA-approved for weight loss in any population.

How long does it take for metformin to start working for weight loss?

Glucose effects begin within days. Weight loss is slow, typically appearing over 3 to 6 months and stabilizing by month 12. There is no rapid drop the way GLP-1s produce.

Is metformin a weight loss pill?

No. Metformin is a diabetes medication that can produce modest weight loss as a side effect. The FDA has not approved it for weight management. Wegovy, Zepbound, Saxenda, and Qsymia are the FDA-approved prescription weight loss medications.

Why do GLP-1s cause more weight loss than metformin?

GLP-1s act directly on appetite centers in the brain, slow gastric emptying, and reduce hunger signaling. Metformin works on liver glucose production and insulin sensitivity without changing appetite, which is why the magnitude is different.

Should I switch from metformin to a GLP-1?

Usually not a swap. Most prescribers add a GLP-1 on top of metformin rather than stopping the metformin. Talk to your clinician about your specific goal before changing either.

How long does topiramate take to work for weight loss?

Topiramate's appetite effect appears at 4 to 8 weeks. Meaningful weight loss usually lands at 3 to 6 months. Qsymia (phentermine plus topiramate ER) produces about 9.8% body weight loss at 1 year, between metformin and the GLP-1s.

Is Topamax a weight loss pill?

Topiramate is FDA-approved for seizures and migraine prevention. It is approved for weight loss only as part of Qsymia, a combination with phentermine. Off-label topiramate alone is sometimes prescribed for weight, but it is not a first-line option.

Can metformin be used for Hashimoto's weight loss?

Metformin does not treat Hashimoto's and is not a weight loss treatment for thyroid-driven weight gain. Correcting thyroid hormone replacement is the right first step. Metformin can be added for coexisting insulin resistance.

Is GLP-1 worth the cost if metformin works?

It depends on your goal. If metformin gets your A1c to target and you are happy with modest weight change, no need to add the cost of a GLP-1. If weight loss is the priority and metformin is not enough, the GLP-1 produces results metformin cannot match.